Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
(4) - EconoTimes)
CAMBRIDGE, Mass., May 01, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, granted equity awards on April 28, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to seven individuals hired by Sarepta in April 2017. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 21,317 shares of Sarepta's common stock. The options have an exercise price of $36.26 per share, which is equal to the closing price of Sarepta's common stock on April 28, 2017. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
